Elritercept
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Accepting patients
RENEW
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
No known participating trial centers
Learn more- Activin Receptor IIA Inhibitor
- Closed Label (Masked)
- Placebo
- Phase 3
Accepting patients
KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more- Growth Factor
- Phase 2
- Has results